Showing 6521-6530 of 8649 results for "".
- Sylentis Presents New Results for the Treatment of AMDhttps://modernod.com/news/sylentis-presents-new-results-for-the-treatment-of-amd/2480173/Sylentis presented preclinical results of a new topically administered molecule (SYL1801), indicated for the treatment of age-related macular degeneration (AMD), at the ARVO meeting. Sylentis presented the abstract “Topical administration of siRNA targeting NRARP as a new treatment
- ReGenTree Presents Results of a Comparison Study of RGN-259 and Approved Prescription Drugs for Dry Eyehttps://modernod.com/news/regentree-presents-results-of-a-comparison-study-of-rgn-259-and-approved-prescription-drugs-for-dry-eye-syndrome-in-a-mouse-model-at-arvo/2480176/ReGenTree announced that the company presented results of a comparison study of RGN-259 and marketed products for dry eye syndrome in a dry eye mouse model at the ARVO meeting. The study was conducted by Jaewook Yan
- Sylentis Announces the Clinical Results of Tivanisiran for the Treatment of Dry Eye Syndromehttps://modernod.com/news/sylentis-announces-the-clinical-results-of-tivanisiran-for-the-treatment-of-dry-eye-syndrome/2480178/At the ARVO meeting, Sylentis presented results from the clinical studies carried out with tivanisiran for the treatment of dry eye syndrome, and that has enabled the start-up of the phase 3 “Helix” clinical trial. Sylentis presented the preclinical and clinical results of vari
- Nicox Presents Scientific Data for NCX 667 at ARVOhttps://modernod.com/news/nicox-presents-scientific-data-for-ncx-667-at-arvo/2480179/Nicox announced a poster presentation highlighting scientific data for NCX 667, a novel nitric oxide (NO) donating compound, at the Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting, one of the key scientific events in the ophthalmology calendar, being held on April
- OWL: Advancing Diversity in Leadership Appoints New Executive Director, Gaynor Frieshttps://modernod.com/news/owl-advancing-diversity-in-leadership-appoints-new-executive-director-gaynor-fries/2480180/OWL: Advancing Diversity in Leadership announced that Gaynor Fries has been appointed Executive Director of the organization. Gaynor has been a key part of the support team behind OWL since July 2015. With a BA in Business Administration and a Certificate in Non-Profit Management from Duke
- Visulytix’s AI Tool Equivalent to Human Experts in Glaucoma Detectionhttps://modernod.com/news/visulytixs-ai-tool-equivalent-to-human-experts-in-glaucoma-detection/2480181/Visulytix announced that Pegasus-disc, its artificial intelligence (AI) decision support tool for the analysis of retinal images, has been shown to perform similarly to the consensus opinion of human experts when detecting glaucoma from optic disc images. This follows a study conducted on the ima
- OCTANe Partners with the CEDARS/ASPENS to Enhance Offeringshttps://modernod.com/news/octane-partners-with-the-cedars-aspens-to-enhance-offerings/2480182/OCTANe announced that it has partnered with the CEDARS/ASPENS Society to enhance offerings around ophthalmic surgery for its annual Ophthalmology Technology Summit (OTS). OTS 2018 will be held June 29 at the Fashion
- Iridex Announces Increase in Micropulse Visibility at ARVOhttps://modernod.com/news/iridex-announces-increase-in-micropulse-visibility-at-arvo/2480183/Iridex has announced that ARVO attendees will have access to over 20 posters presenting data on the use of MicroPulse technology. Eleven studies cover the use of MicroPulse technology for the treatment of glaucoma while the remaining studies present data on the use of MicroPulse for diverse patho
- Ocugen Presents Preclinical Efficacy Data of its Proprietary Nanoemulsion Technology at ARVO 2018https://modernod.com/news/ocugen-presents-preclinical-efficacy-data-of-its-proprietary-nanoemulsion-technology-at-arvo-2018/2480184/Ocugen announced that it presented additional preclinical findings in a poster highlighting the potential efficacy of its unique, patented nanoemulsion formulation of brimonidine tartrate (OCU300) at the Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting, held
- ReGenTree Presents Results of a Comparison Study of RGN-259 and Approved Prescription Drugs for Dry Eye Syndromehttps://modernod.com/news/regentree-presents-results-of-a-comparison-study-of-rgn-259-and-approved-prescription-drugs-for-dry-eye-syndrome/2480185/ReGenTree, a joint venture between GtreeBNT and RegeneRx Biopharmaceuticals, announced that the company presented results of a comparison study of RGN-259 and marketed products for dry eye syndrome in a dry eye mouse model at ARVO (The Association for Research in Vision and Ophthalmology)